Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
The recent approval by the US Food and Drug Administration (FDA) of Moderna’s (Nasdaq: MRNA) respiratory syncytial virus (RSV) vaccine mRESVIA represents a significant development in the field and will likely encourage the use of mRNA technology across other disciplines. 7 June 2024
Biotechnology
Moderna has announced that the US Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. 6 June 2024
Biotechnology
Gilead Sciences has announced data from the Phase IIb MYR204 open-label study assessing the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in compensated chronic hepatitis delta virus (HDV) infection. 6 June 2024
Biotechnology
Shares in California’s Vir Biotechnology closed 20% higher after Wednesday’s trading, on promising new research data. 6 June 2024
Biotechnology
Top-line data from the randomized, placebo-controlled Phase III MITIGATE study demonstrated Uplizna (inebilizumab) met all primary and key secondary endpoints in treating immunoglobulin G4-related disease (IgG4-RD), US biotech major Amgen announced. 5 June 2024
Biotechnology
Maryland, USA-based I-Mab has announced a new clinical trial collaboration with cancer giant Bristol Myers Squibb. 5 June 2024
Pharmaceutical
US biotech major Gilead Sciences has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. 5 June 2024
Biotechnology
Vilya, a biotechnology company focused on designing novel medicines, has announced a $71 million expansion of its series A financing. 5 June 2024
Pharmaceutical
Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation announced that it has appointed Aaron Berg, currently Amarin’s executive vice president and president of the US business, as president and chief executive (CEO). 5 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze